Aviram Mizrachi

The Global Immune–Nutrition–Inflammation Index (GINI) as a Candidate Prognostic Marker in Patients with Cutaneous Squamous Cell Carcinoma Treated with Cemiplimab

Background/Objectives: Cutaneous squamous cell carcinoma (cSCC) is a highly prevalent malignancy. While Cemiplimab has transformed the treatment landscape across various disease stages, reliable pretreatment biomarkers for risk stratification remain lacking.. The Global Immune–Nu...